<DOC>
	<DOCNO>NCT01222286</DOCNO>
	<brief_summary>The purpose study evaluate anti-tumor activity , safety pharmacology two dose regimen ( 0.2 2 mg/kg ) IPH2101 patient Smoldering Multiple Myeloma .</brief_summary>
	<brief_title>Study Anti-tumor Activity , Safety Pharmacology IPH2101 Patients With Smoldering Multiple Myeloma</brief_title>
	<detailed_description>This randomized Phase II , open label , multi-centre study , two independent arm . Patients receive 6 injection IPH2101 , dose 0.2 mg/kg 2 mg/kg ( accord randomization ) administer one hour infusion four week interval . A patient whose disease achieve least minimal response study treatment time initial period 6 cycle treat additional period treatment 6 cycle . Patients follow 6 month treatment completion KIR occupancy level &lt; 30 % ( i.e time require KIR desaturation &gt; 6 month ) , whichever longer .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . SMM risk level accord definition derive International Myeloma Working Group definition ( Br J Haematol 2003 ; 121 : 749 ) : Serum M protein ≥ 3 g/dl , AND/OR Bone Marrow plasma cell ≥ 10 % evidence endorgan damage ( CRAB ) ( C ) Absence hypercalcemia : Ca &lt; 10.5 mg/dl ( R ) Absence renal failure : creatinine &lt; 2mg/dl ( 177 μmol/l ) calculate creatinine clearance ( accord MDRD ) &gt; 50 ml/min ( A ) Absence anemia : Hb &gt; 11 g/dl ( B ) Absence lytic bone lesion standard skeletal survey ( MRI could use clinically indicate ) 2 . Measurable disease define disease serum M protein ≥ 1 g/dl 3 . No evidence fatigue , recurrent infection clinical suspicion MM 4 . Diagnosis SMM confirm two consecutive assessment ( ie fluctuation 25 % serum protein level ) perform least 4 week interval . 5 . Age &gt; 18 year &lt; 75 year 6 . ECOG performance status 0 1 7 . Male female patient accepts able use recognise effective contraception ( oral contraceptive , IUCD , barrier method contraception conjunction spermicidal jelly ) throughout study relevant 8 . Informed consent sign patient 1 . Previous treatment proven potential impact myelomatous cell proliferation survival ( include IMiDs proteasome inhibitor , conventional chemotherapy within last 5 year , steroid within last month prior enrolment ) . Previous bisphosphonates start less 3 month prior enrolment . 2 . Use investigational agent within last 3 month 3 . Clinical laboratory value screen Platelet &lt; 75 x 10^9 /l ANC &lt; 1.5 x 10^9 /l Bilirubin level &gt; 1.5 ULN ; ALT AST &gt; 3 ULN ( grade 1 NCI ) 4 . Primary associate amyloidosis 5 . Abnormal cardiac status follow 1 . NYHA stage III IV congestive heart failure 2. myocardial infarction within previous 6 month 3. symptomatic cardiac arrhythmia require treatment persist despite appropriate treatment 6 . Current active infectious disease positive serology HIV , HCV positive Hbs Antigen 7 . History current autoimmune disease 8 . History active malignancy within past five year ( apart basal cell carcinoma skin , situ cervix carcinoma ) . 9 . Serious concurrent uncontrolled medical disorder 10 . History allograft solid organ transplantation 11 . Pregnant lactate woman 12 . Any condition potentially hamper compliance study protocol followup schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Smoldering Multiple Myeloma</keyword>
</DOC>